Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …

The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …

Objective To evaluate the prevalence, duration and effect on damage accrual of the 'Lupus
Low Disease Activity State'(LLDAS) in a monocentric cohort of patients with systemic lupus …

Background Treat-to-target strategies have improved outcomes in single-organ diseases
with simple clinical or laboratory endpoints. A lack of validated endpoints has prevented …

Background Systemic lupus erythematosus (SLE) is associated with significant impairment
of health-related quality of life (HR-QoL). Recently, meeting a definition of a lupus low …

Objective Damage in patients with systemic lupus erythematosus is irreversible change in
organs due to disease activity, concomitant disease or medication side-effects. It is …

Treat-to-target strategies have changed the approach to management of many chronic
conditions, with improvements in patient outcomes. The key to success of treat to target is …

Objectives To evaluate what proportion of patients fulfil the DORIS definition of remission,
the definition of lupus low disease activity state (LLDAS) and LLDAS with a glucocorticoid …

Background The aim was to assess the attainability and outcome of the lupus low disease
activity state (LLDAS) in the early stages of systemic lupus erythematosus (SLE). Methods …